Sweet's syndrome triggered by COVID-19

Authors

  • María Gimena Polimeni Professor Alejandro Posadas National Hospital, Province of Buenos Aires, Argentina
  • Patricia Silvia Della Giovanna Professor Alejandro Posadas National Hospital, Province of Buenos Aires, Argentina
  • Diego Martín Loriente Professor Alejandro Posadas National Hospital, Province of Buenos Aires, Argentina
  • Carmen Tatiana Alfaro Professor Alejandro Posadas National Hospital, Province of Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/da.v31i2.2873

Keywords:

Sweet's syndrome, acute myeloid leukemia, COVID-19

Abstract

Sweet syndrome or acute febrile neutrophilic dermatosis is a rare and probably underdiagnosed entity. In recent years, cases of Sweet syndrome met both with COVID-19 infection and with its vaccines. We report the first case in the national literature of a patient with a history of acute myeloid leukemia who presented Sweet syndrome secondary to SARS-CoV-2 disease.

Author Biographies

  • María Gimena Polimeni, Professor Alejandro Posadas National Hospital, Province of Buenos Aires, Argentina

    Third-Year Medical Trainee, Dermatology Specialist Program, University of Buenos Aires (BA)

  • Patricia Silvia Della Giovanna, Professor Alejandro Posadas National Hospital, Province of Buenos Aires, Argentina

    Dermatologist, Head of the Dermatology Service

  • Diego Martín Loriente, Professor Alejandro Posadas National Hospital, Province of Buenos Aires, Argentina

    Dermatologist

  • Carmen Tatiana Alfaro, Professor Alejandro Posadas National Hospital, Province of Buenos Aires, Argentina

    Pathologist

References

I. Strong J, Zhou AE, Alkaabba F, Soldin D, et ál. A case of acute myeloid leukemia-associated necrotizing Sweet syndrome. Dermatol. 2022;14:339-343.

II. Orfaly VE, Shakshouk H, Heath M, Hamilton A, et ál. Sweet syndrome: a review of published cases. Dermatology. 2023;239:664-669.

III. Uy GL, Aldoss I, Foster MC, Sayre PH, et ál. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. 2021;137:751-762.

IV. Villarreal-Villarreal CD, Ocampo-Candiani J, Villarreal-Martínez A. Sweet syndrome: a review and update. Actas Dermosifiliogr. 2016;107:369-378.

V. Chelly I, Zehani A, Mbazaa A, Azouz H, et ál. Syndrome de Sweet: étude rétrospective de 47 cas. Rev Med Interne. 2013;34:197-201.

VI. Fonseca GSD, Pinto AFDA, Silveira SCF, Silva JHDAE, et ál. Sweet's syndrome during induction chemotherapy for acute myeloid leukemia: case report and mini review. Hematol Transfus Cell Ther. 2021;43:374-376.

VII. Merlant M, Lepelletier C, Battistella M, Vignon-Pennamen MD, et ál. Acute myeloid leukemia and myelodysplastic syndrome-associated Sweet syndrome. A comparative multicenter retrospective study of 39 patients. J Am Acad Dermatol. 2021;84:838-840.

VIII. Agharbi FZ, Oqbani K, Allaoui A, Chikhaoui I, et ál Sweet syndrome in post-COVID-19 infection: a case report. Travel Med Infect Dis. 2021;44:102188.

IX. Ferea CR, Mihai SN, Balan G, Badescu MC, et ál. Sweet Syndrome associated with myelodysplastic syndrome. A review of a multidisciplinary approach. Life (Basel). 2023; 13:809.

X. Joshi TP, Dokic Y, Verstovsek G, Rosen T. A case of filgrastim-induced neutrophilic dermatosis of the dorsal hands in a patient with Felty syndrome. Dermatol Online J. 2023;29.

Downloads

Published

2025-08-01

Issue

Vol. 31 No. 2 (2025): May-August

Section

Clinical Cases

License

Copyright (c) 2025 on behalf of the authors. Reproduction rights: Argentine Society of Dermatology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

El/los autor/es tranfieren todos los derechos de autor del manuscrito arriba mencionado a Dermatología Argentina en el caso de que el trabajo sea publicado. El/los autor/es declaran que el artículo es original, que no infringe ningún derecho de propiedad intelectual u otros derechos de terceros, que no se encuentra bajo consideración de otra revista y que no ha sido previamente publicado.

 

Le solicitamos haga click aquí para imprimir, firmar y enviar por correo postal la transferencia de los derechos de autor